Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational... see more

NDAQ:PMN - Post Discussion

ProMIS Neurosciences Inc > infomercial
View:
Post by M101 on Feb 26, 2024 4:38pm

infomercial

I guess when you're paid to write propaganda you slip in the occasional lame joke just for sanity.

"Elan’s vaccination study, in particular, created numerous headaches for DeMattos. The clinical trial was quickly halted in 2002 after several patients developed severe brain inflammation. "
https://endpts.com/failure-faith-and-8-billion-how-lillys-amyloid-conviction-brought-it-to-the-brink-of-alzheimers-approval/

I wonder what chapters are already written for the eventual Promis bio? 
The prion revelation?
The Goldstein years?
Dilution for control?
To Nasdaq and back?
Comment by garygp on Feb 27, 2024 2:50pm
M101 You could use any one of your above noted chapters and write a compelling story on the abuse shareholders have taken at the hands of all BOD members over the past 20 years. But, what the he!!.  Use all four ideas and go for Best Seller status at the bookstores.  I don't believe ProMIS are known in any pharmaceutical circles, certainly none that follow.  Goldstein did a ...more  
Comment by M101 on Feb 27, 2024 4:39pm
If the market really turns south this year, as I believe it will, then we'll be somewhat relieved that the Boston Group is in for the long term and can absorb any remaining weak hands. I have no reason to think Goldstein ever turned down a decent offer, why would he?  So the relevant question is why there is no market interest? Well, who goes to a casino to make a 10 year bet? Because ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities